Download PDF
Horm Metab Res 2019; 51(07): 414-418
DOI: 10.1055/a-0586-3710
Review

Diagnostic Investigation of Lesions Associated with Succinate Dehydrogenase Defects

David Taïeb
1   Department of Nuclear Medicine, La Timone University Hospital, CERIMED, Aix-Marseille University, Marseille, France
,
Henri Timmers
2   Department of Internal Medicine, Division of Endocrinology, Radboud University Medical Centre, Nijmegen, The Netherlands
,
Karel Pacak
3   Section on Medical Neuroendocrinology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, USA
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Abstract

The mitochondrial enzyme succinate dehydrogenase (SDH) acts as a tumor suppressor. Biallelic inactivation of one of the genes encoding for SDH subunits (collectively named SDHx) leads to complete loss of the protein function and the development of diverse group of tumors. Pheochromocytomas-paragangliomas are the prime example of hereditary tumors caused by SDH deficiency. In this review, we discuss the roles of imaging examinations, and illustrate new insights into genotype-imaging phenotype relationships.

Key words

positron emission tomography - gallium radioisotopes - 6-(18F)fluoro-l-3 - 4-dihydroxyphenylalanine - precision medicine - theranostics - succinate dehydrogenase


Publication History

Received: 05 November 2017

Accepted: 28 February 2018

Article published online:
04 April 2018

Georg Thieme Verlag
Rüdigerstraße 14,70469 Stuttgart, Germany

 

  • References

  • 1 Unsicker K, Huber K, Schober A, Kalcheim C. Resolved and open issues in chromaffin cell development. Mech Dev 2013; 130: 324-329
    CrossrefPubMedGoogle Scholar
  • 2 Crona J, Taieb D, Pacak K. New perspectives on pheochromocytoma and paraganglioma: Towards a molecular classification. Endocr Rev 2017; 38: 489-515
    CrossrefPubMedGoogle Scholar
  • 3 Fishbein L, Leshchiner I, Walter V, Danilova L, Robertson AG, Johnson AR, Lichtenberg TM, Murray BA, Ghayee HK, Else T, Ling S, Jefferys SR, de Cubas AA, Wenz B, Korpershoek E, Amelio AL, Makowski L, Rathmell WK, Gimenez-Roqueplo AP, Giordano TJ, Asa SL, Tischler AS, Cancer Genome Atlas Research N. Pacak K, Nathanson KL, Wilkerson MD. Comprehensive molecular characterization of pheochromocytoma and paraganglioma. Cancer Cell 2017; 31: 181-193
    CrossrefPubMedGoogle Scholar
  • 4 Baysal BE, Ferrell RE, Willett-Brozick JE, Lawrence EC, Myssiorek D, Bosch A, van der Mey A, Taschner PE, Rubinstein WS, Myers EN, Richard 3rd CW, Cornelisse CJ, Devilee P, Devlin B. Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science 2000; 287: 848-851
    CrossrefPubMedGoogle Scholar
  • 5 Niemann S, Muller U. Mutations in SDHC cause autosomal dominant paraganglioma, type 3. Nat Genet 2000; 26: 268-270
    CrossrefPubMedGoogle Scholar
  • 6 Astuti D, Latif F, Dallol A, Dahia PL, Douglas F, George E, Skoldberg F, Husebye ES, Eng C, Maher ER. Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma. Am J Hum Genet 2001; 69: 49-54
    CrossrefPubMedGoogle Scholar
  • 7 Burnichon N, Briere JJ, Libe R, Vescovo L, Riviere J, Tissier F, Jouanno E, Jeunemaitre X, Benit P, Tzagoloff A, Rustin P, Bertherat J, Favier J, Gimenez-Roqueplo AP. SDHA is a tumor suppressor gene causing paraganglioma. Hum Mol Genet 2010; 19: 3011-3020
    CrossrefPubMedGoogle Scholar
  • 8 Hao HX, Khalimonchuk O, Schraders M, Dephoure N, Bayley JP, Kunst H, Devilee P, Cremers CW, Schiffman JD, Bentz BG, Gygi SP, Winge DR, Kremer H, Rutter J. SDH5, a gene required for flavination of succinate dehydrogenase, is mutated in paraganglioma. Science 2009; 325: 1139-1142
    CrossrefPubMedGoogle Scholar
  • 9 Haller F, Moskalev EA, Faucz FR, Barthelmess S, Wiemann S, Bieg M, Assie G, Bertherat J, Schaefer IM, Otto C, Rattenberry E, Maher ER, Strobel P, Werner M, Carney JA, Hartmann A, Stratakis CA, Agaimy A. Aberrant DNA hypermethylation of SDHC: A novel mechanism of tumor development in Carney triad. Endocr Relat Cancer 2014; 21: 567-577
    CrossrefPubMedGoogle Scholar
  • 10 Tannahill GM, Curtis AM, Adamik J, Palsson-McDermott EM, McGettrick AF, Goel G, Frezza C, Bernard NJ, Kelly B, Foley NH, Zheng L, Gardet A, Tong Z, Jany SS, Corr SC, Haneklaus M, Caffrey BE, Pierce K, Walmsley S, Beasley FC, Cummins E, Nizet V, Whyte M, Taylor CT, Lin H, Masters SL, Gottlieb E, Kelly VP, Clish C, Auron PE, Xavier RJ, O'Neill LA. Succinate is an inflammatory signal that induces IL-1beta through HIF-1alpha. Nature 2013; 496: 238-242
    CrossrefPubMedGoogle Scholar
  • 11 Mu X, Zhao T, Xu C, Shi W, Geng B, Shen J, Zhang C, Pan J, Yang J, Hu S, Lv Y, Wen H, You Q. Oncometabolite succinate promotes angiogenesis by upregulating VEGF expression through GPR91-mediated STAT3 and ERK activation. Oncotarget 2017; 8: 13174-13185
    CrossrefPubMedGoogle Scholar
  • 12 Benn DE, Robinson BG, Clifton-Bligh RJ. 15 YEARS OF PARAGANGLIOMA: Clinical manifestations of paraganglioma syndromes types 1-5. Endocr Relat Cancer 2015; 22: T91-T103
    CrossrefPubMedGoogle Scholar
  • 13 Schiavi F, Boedeker CC, Bausch B, Peczkowska M, Gomez CF, Strassburg T, Pawlu C, Buchta M, Salzmann M, Hoffmann MM, Berlis A, Brink I, Cybulla M, Muresan M, Walter MA, Forrer F, Valimaki M, Kawecki A, Szutkowski Z, Schipper J, Walz MK, Pigny P, Bauters C, Willet-Brozick JE, Baysal BE, Januszewicz A, Eng C, Opocher G, Neumann HP. European-American Paraganglioma Study G. Predictors and prevalence of paraganglioma syndrome associated with mutations of the SDHC gene. JAMA 2005; 294: 2057-2063
    CrossrefPubMedGoogle Scholar
  • 14 Taieb D, Pacak K. New insights into the nuclear imaging phenotypes of cluster 1 pheochromocytoma and paraganglioma. Trends Endocrinol Metab 2017; 28: 807-817
    CrossrefPubMedGoogle Scholar
  • 15 Garrigue P, Bodin-Hullin A, Balasse L, Fernandez S, Essamet W, Dignat-George F, Pacak K, Guillet B, Taieb D. The evolving role of succinate in tumor metabolism: An (18)F-FDG-based study. J Nucl Med 2017; 58: 1749-1755
    CrossrefPubMedGoogle Scholar
  • 16 Gabriel S, Blanchet EM, Sebag F, Chen CC, Fakhry N, Deveze A, Barlier A, Morange I, Pacak K, Taieb D. Functional characterization of nonmetastatic paraganglioma and pheochromocytoma by (18) F-FDOPA PET: Focus on missed lesions. Clin Endocrinol 2013; 79: 170-177
    CrossrefPubMedGoogle Scholar
  • 17 Feral CC, Tissot FS, Tosello L, Fakhry N, Sebag F, Pacak K, Taieb D. 18 F-fluorodihydroxyphenylalanine PET/CT in pheochromocytoma and paraganglioma: Relation to genotype and amino acid transport system L. Eur J Nucl Med Mol Imaging 2017; 44: 812-821
    CrossrefPubMedGoogle Scholar
  • 18 Darr R, Nambuba J, Del Rivero J, Janssen I, Merino M, Todorovic M, Balint B, Jochmanova I, Prchal JT, Lechan RM, Tischler AS, Popovic V, Miljic D, Adams KT, Prall FR, Ling A, Golomb MR, Ferguson M, Nilubol N, Chen CC, Chew E, Taieb D, Stratakis CA, Fojo T, Yang C, Kebebew E, Zhuang Z, Pacak K. Novel insights into the polycythemia-paraganglioma-somatostatinoma syndrome. Endocr Relat Cancer 2016; 23: 899-908
    CrossrefPubMedGoogle Scholar
  • 19 Janssen I, Blanchet EM, Adams K, Chen CC, Millo CM, Herscovitch P, Taieb D, Kebebew E, Lehnert H, Fojo AT, Pacak K. Superiority of [68Ga]-DOTATATE PET/CT to Other functional imaging modalities in the localization of SDHB-associated metastatic pheochromocytoma and paraganglioma. Clin Cancer Res 2015; 21: 3888-3895
    CrossrefPubMedGoogle Scholar
  • 20 Archier A, Varoquaux A, Garrigue P, Montava M, Guerin C, Gabriel S, Beschmout E, Morange I, Fakhry N, Castinetti F, Sebag F, Barlier A, Loundou A, Guillet B, Pacak K, Taieb D. Prospective comparison of (68)Ga-DOTATATE and (18)F-FDOPA PET/CT in patients with various pheochromocytomas and paragangliomas with emphasis on sporadic cases. Eur J Nucl Med Mol Imaging 2016; 43: 1248-1257
    CrossrefPubMedGoogle Scholar
  • 21 Kroiss A, Putzer D, Frech A, Decristoforo C, Uprimny C, Gasser RW, Shulkin BL, Url C, Widmann G, Prommegger R, Sprinzl GM, Fraedrich G, Virgolini IJ. A retrospective comparison between 68Ga-DOTA-TOC PET/CT and 18 F-DOPA PET/CT in patients with extra-adrenal paraganglioma. Eur J Nuc Med Mol Imaging 2013; 40: 1800-1808
    CrossrefPubMedGoogle Scholar
  • 22 van den Berg R, Schepers A, de Bruine FT, Liauw L, Mertens BJ, van der Mey AG, van Buchem MA. The value of MR angiography techniques in the detection of head and neck paragangliomas. Eur J Radiol 2004; 52: 240-245
    CrossrefPubMedGoogle Scholar
  • 23 van den Berg R, Wasser MN, van Gils AP, van der Mey AG, Hermans J, van Buchem MA. Vascularization of head and neck paragangliomas: Comparison of three MR angiographic techniques with digital subtraction angiography. AJNR Am J Neuroradiol 2000; 21: 162-170
    PubMedGoogle Scholar
  • 24 Ferre JC, Brunet JF, Carsin-Nicol B, Larralde A, Godey B, Gauvrit JY. Optimized time-resolved 3D contrast-enhanced MRA at 3 T: Appreciating the feasibility of assessing cervical paragangliomas. J Neuroradiol 2010; 37: 104-108
    CrossrefPubMedGoogle Scholar
  • 25 Neves F, Huwart L, Jourdan G, Reizine D, Herman P, Vicaut E, Guichard JP. Head and neck paragangliomas: Value of contrast-enhanced 3D MR angiography. AJNR Am J Neuroradiol 2008; 29: 883-889
    CrossrefPubMedGoogle Scholar
  • 26 Taieb D, Varoquaux A, Chen CC, Pacak K. Current and future trends in the anatomical and functional imaging of head and neck paragangliomas. Semin Nucl Med 2013; 43: 462-473
    CrossrefPubMedGoogle Scholar
  • 27 Taieb D, Kaliski A, Boedeker CC, Martucci V, Fojo T, Adler Jr. JR, Pacak K. Current approaches and recent developments in the management of head and neck paragangliomas. Endocr Rev 2014; 35: 795-819
    CrossrefPubMedGoogle Scholar
  • 28 Heimburger C, Veillon F, Taieb D, Goichot B, Riehm S, Petit-Thomas J, Averous G, Cavalcanti M, Hubele F, Chabrier G, Namer IJ, Charpiot A, Imperiale A. Head-to-head comparison between 18 F-FDOPA PET/CT and MR/CT angiography in clinically recurrent head and neck paragangliomas. Eur J Nucl Med Mol Imaging 2017; 44: 979-987
    CrossrefPubMedGoogle Scholar
  • 29 Siegel JA, Sacks B, Pennington CW, Welsh JS. Dose Optimization to Minimize Radiation Risk for Children Undergoing CT and Nuclear Medicine Imaging Is Misguided and Detrimental. J Nucl Med 2017; 58: 865-868
    CrossrefPubMedGoogle Scholar
  • 30 Daniel E, Jones R, Bull M, Newell-Price J. Rapid-sequence MRI for long-term surveillance for paraganglioma and phaeochromocytoma in patients with succinate dehydrogenase mutations. Eur J Endocrinol 2016; 175: 561-570
    CrossrefPubMedGoogle Scholar
  • 31 Lussey-Lepoutre C, Bellucci A, Morin A, Buffet A, Amar L, Janin M, Ottolenghi C, Zinzindohoue F, Autret G, Burnichon N, Robidel E, Banting B, Fontaine S, Cuenod CA, Benit P, Rustin P, Halimi P, Fournier L, Gimenez-Roqueplo AP, Favier J, Tavitian B. In vivo detection of succinate by magnetic resonance spectroscopy as a hallmark of SDHx mutations in paraganglioma. Clin Cancer Res 2016; 22: 1120-1129
    CrossrefPubMedGoogle Scholar
  • 32 Varoquaux A, le Fur Y, Imperiale A, Reyre A, Montava M, Fakhry N, Namer IJ, Moulin G, Pacak K, Guye M, Taieb D. Magnetic resonance spectroscopy of paragangliomas: New insights into in vivo metabolomics. Endocr Relat Cancer 2015; 22: M1-M8
    CrossrefPubMedGoogle Scholar